CBD Oil Cause Dry Mouth

CBDISTILLERY

Buy CBD Oil Online

Learn more about CANNABIDIOL (CBD) uses, effectiveness, possible side effects, interactions, dosage, user ratings and products that contain CANNABIDIOL (CBD). Ever wondered why CBD causes the dry mouth effect? This article explains why it happens and how to deal with dry mouth after taking CBD oil. Do CBD supplements leave an unpleasant dryness in your mouth? Here’s why it happens and what you can do about this constant dry and pasty mouth sensation.

CANNABIDIOL (CBD) – Uses, Side Effects, and More

Cannabidiol (CBD) is a chemical in the Cannabis sativa plant, also known as cannabis or hemp. One specific form of CBD is approved as a drug in the U.S. for seizures.

Over 80 chemicals, known as cannabinoids, have been found in the Cannabis sativa plant. Delta-9-tetrahydrocannabinol (THC) is the most famous ingredient in cannabis. But CBD is obtained from hemp, a form of the Cannabis sativa plant that only contains small amounts of THC. CBD seems to have effects on some chemicals in the brain, but these are different than the effects of THC.

A prescription form of CBD is used for seizure disorder (epilepsy). CBD is also used for anxiety, pain, a muscle disorder called dystonia, Parkinson disease, Crohn disease, and many other conditions, but there is no good scientific evidence to support these uses.

Laws passed in 2018 made it legal to sell hemp and hemp products in the US. But that doesn’t mean that all CBD products made from hemp are legal. Since CBD is an approved prescription drug, it can’t be legally included in foods or dietary supplements. CBD can only be included in “cosmetic” products. But there are still CBD products on the market that are labeled as dietary supplements. The amount of CBD contained in these products is not always the same as what is stated on the label.

How does it work ?

Uses & Effectiveness ?

Likely Effective for

  • Seizure disorder (epilepsy). A specific prescription product (Epidiolex, GW Pharmaceuticals) is approved by the US FDA to treat seizures caused by Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex. It is unclear if other forms of CBD are helpful for seizure. For now, stick with the prescription product.

Possibly Effective for

    (MS). A prescription-only nasal spray product (Sativex, GW Pharmaceuticals) containing both 9-delta-tetrahydrocannabinol (THC) and cannabidiol has been shown to be effective for improving pain, muscle-tightness, and urination frequency in people with MS. This product is used in over 25 countries outside of the United States. But there is inconsistent evidence on the effectiveness of cannabidiol for symptoms of multiple sclerosis when it is used alone. Some early research suggests that using a cannabidiol spray under the tongue might improve pain and muscle tightness, but not muscle spasms, tiredness, bladder control, mobility, or well-being and quality of life in patients with MS.

Side Effects

When taken by mouth: CBD is possibly safe to take in appropriate doses. Doses of up to 200 mg daily have been used safely for up to 13 weeks. With the guidance of a healthcare provider, a specific prescription CBD product (Epidiolex) has been used at higher doses and for longer durations.

CBD can cause some side effects, such as dry mouth, low blood pressure, light headedness, and drowsiness. Signs of liver injury have also been reported with high doses of the prescription form of CBD, called Epidiolex.

When applied to the skin: There isn’t enough reliable information to know if CBD is safe or what the side effects might be.

Special Precautions and Warnings

Pregnancy and breast-feeding: It may be unsafe to take CBD if you are pregnant or breast feeding. CBD products can be contaminated with other ingredients that may be harmful to the fetus or infant. Stay on the safe side and avoid use.

Children: It is possibly safe for children to take a specific prescription CBD product (Epidiolex) by mouth in doses up to 25 mg/kg daily. This product is approved for use in children with certain conditions who are at least 1 year old. It isn’t clear if other CBD products are safe in children.

Liver disease: People with liver disease may need to use lower doses of CBD.

Parkinson disease: Some early research suggests that taking high doses of CBD might make muscle movement and tremors worse in some people with Parkinson disease.

Interactions ?

Moderate Interaction

Be cautious with this combination

Medications changed by the liver (Cytochrome P450 1A1 (CYP1A1) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 1B1 (CYP1B1) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 2A6 (CYP2A6) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 2B6 (CYP2B6) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Sedative medications (CNS depressants) interacts with CANNABIDIOL (CBD)

CBD might cause sleepiness and slowed breathing. Some medications, called sedatives, can also cause sleepiness and slowed breathing. Taking CBD with sedative medications might cause breathing problems and/or too much sleepiness.

Clobazam (Onfi) interacts with CANNABIDIOL (CBD)

Clobazam is changed and broken down by the liver. CBD might decrease how quickly the liver breaks down clobazam. This might increase the effects and side effects of clobazam.

Eslicarbazepine (Aptiom) interacts with CANNABIDIOL (CBD)

Eslicarbazepine is changed and broken down by the body. CBD might decrease how quickly the body breaks down eslicarbazepine. This might increase levels of eslicarbazepine in the body by a small amount.

Rufinamide (Banzel) interacts with CANNABIDIOL (CBD)

Rufinamide is changed and broken down by the body. CBD might decrease how quickly the body breaks down rufinamide. This might increase levels of rufinamide in the body by a small amount.

Topiramate (Topamax) interacts with CANNABIDIOL (CBD)

Topiramate is changed and broken down by the body. CBD might decrease how quickly the body breaks down topiramate. This might increase levels of topiramate in the body by a small amount.

Valproate interacts with CANNABIDIOL (CBD)

Valproic acid can cause liver injury. Taking cannabidiol with valproic acid might increase the chance of liver injury. CBD and/or valproic acid might need to be stopped, or the dose might need to be reduced.

Zonisamide interacts with CANNABIDIOL (CBD)

Zonisamide is changed and broken down by the body. CBD might decrease how quickly the body breaks down zonisamide. This might increase levels of zonisamide in the body by a small amount.

Medications changed by the liver (Cytochrome P450 2C8 (CYP2C8) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications changed by the liver (Glucuronidated drugs) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Medications that increase the breakdown of other medications by the liver (Cytochrome P450 2C19 (CYP2C19) inducers) interacts with CANNABIDIOL (CBD)

CBD is changed and broken down by the liver. Some drugs increase how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD.

Medications that increase breakdown of other medications by the liver (Cytochrome P450 3A4 (CYP3A4) inducers) interacts with CANNABIDIOL (CBD)

CBD is changed and broken down by the liver. Some drugs increase how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD.

Medications that decrease the breakdown of other medications by the liver (Cytochrome P450 2C19 (CYP2C19) inhibitors) interacts with CANNABIDIOL (CBD)

CBD is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD.

Medications that decrease the breakdown of other medications in the liver (Cytochrome P450 3A4 (CYP3A4) inhibitors) interacts with CANNABIDIOL (CBD)

CBD is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD.

Brivaracetam (Briviact) interacts with CANNABIDIOL (CBD)

Brivaracetam is changed and broken down by the body. CBD might decrease how quickly the body breaks down brivaracetam. This might increase levels of brivaracetam in the body.

Everolimus (Zostress) interacts with CANNABIDIOL (CBD)

Everolimus is changed and broken down by the body. CBD might decrease how quickly the body breaks down everolimus. This might increase levels of everolimus in the body.

Tacrolimus (Prograf) interacts with CANNABIDIOL (CBD)

Tacrolimus is changed and broken down by the body. CBD might decrease how quickly the body breaks down tacrolimus. This might increase levels of tacrolimus in the body.

Methadone (Dolophine) interacts with CANNABIDIOL (CBD)

Methadone is broken down by the liver. CBD might decrease how quickly the liver breaks down methadone. Taking cannabidiol along with methadone might increase the effects and side effects of methadone.

Carbamazepine (Tegretol) interacts with CANNABIDIOL (CBD)

Carbamazepine is changed and broken down by the body. CBD might decrease how quickly the body breaks down carbamazepine. This might increase levels of carbamazepine in the body and increase its side effects.

Sirolimus (Rapamune) interacts with CANNABIDIOL (CBD)

Sirolimus is changed and broken down by the body. CBD might decrease how quickly the body breaks down sirolimus. This might increase levels of sirolimus in the body.

Stiripentol (Diacomit) interacts with CANNABIDIOL (CBD)

Stiripentol is changed and broken down by the body. CBD might decrease how quickly the body breaks down stiripentol. This might increase levels of stiripentol in the body and increase its side effects.

Lithium interacts with CANNABIDIOL (CBD)

Taking higher doses of CBD might increase levels of lithium. This can increase the risk of lithium toxicity.

Warfarin interacts with CANNABIDIOL (CBD)

CBD might increase levels of warfarin, which can increase the risk for bleeding. CBD and/or warfarin might need to be stopped, or the dose might need to be reduced.

Tamoxifen (Soltamox) interacts with CANNABIDIOL (CBD)

Tamoxifen is changed and broken down by the body. CBD might affect how quickly the body breaks down tamoxifen. This might affect levels of tamoxifen in the body.

Caffeine interacts with CANNABIDIOL (CBD)

Caffeine is changed and broken down by the body. CBD might decrease how quickly the body breaks down caffeine. This might increase levels of caffeine in the body.

Citalopram (Celexa) interacts with CANNABIDIOL (CBD)

Citalopram is changed and broken down by the body. CBD might decrease how quickly the body breaks down citalopram. This might increase levels of citalopram in the body and increase its side effects.

Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates) interacts with CANNABIDIOL (CBD)

Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Dosing

CBD has most often been used by adults in doses of 200 mg or less per day. Speak with a healthcare provider to find out what dose might be best for a specific condition.

For information on using prescription CBD, a product called Epidiolex, speak with a healthcare provider.

Ames, F. R. and Cridland, S. Anticonvulsant effect of cannabidiol. S.Afr.Med.J. 1-4-1986;69(1):14. View abstract.

Barnes, M. P. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert.Opin.Pharmacother. 2006;7(5):607-615. View abstract.

Carlini, E. A. and Cunha, J. M. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-427S. View abstract.

Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur.J.Neurol. 2007;14(3):290-296. View abstract.

Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol.Res. 2010;32(5):451-459. View abstract.

Consroe, P., Kennedy, K., and Schram, K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem.Behav. 1991;40(3):517-522. View abstract.

Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem.Behav. 1991;40(3):701-708. View abstract.

Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21(3):175-185. View abstract.

Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem.Behav. 1991;40(3):523-532. View abstract.

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A. A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134-141. View abstract.

Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., and Hollister, L. E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed.Environ Mass Spectrom. 1986;13(2):77-83. View abstract.

Srivastava, M. D., Srivastava, B. I., and Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998;40(3):179-185. View abstract.

Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ’90 International Conference on Cannabis and Cannabinoids 1990;2:5.

Wade, D. T., Collin, C., Stott, C., and Duncombe, P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult.Scler. 2010;16(6):707-714. View abstract.

Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult.Scler. 2004;10(4):434-441. View abstract.

Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin.Rehabil. 2003;17(1):21-29. View abstract.

Watzl, B., Scuderi, P., and Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13(8):1091-1097. View abstract.

Aviello G, Romano B, Borrelli F, et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 2012;90(8):925-34. View abstract.

Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36(6):1219-26. View abstract.

Bisogno T, Di Marzo Y. The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses. Curr Pharm Des 2008;14(23):2299-3305. View abstract.

Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011;51(5):1054-61. View abstract.

Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45(6):1323-31. View abstract.

Brady CM, DasGupta R, Dalton C, et al. An open-label study of cannabis-based extracts for bladder dysfuntion in advanced multiple sclerosis. Mult Scler 2004;10(4):425-33. View abstract.

Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012;367(1607):3364-78. View abstract.

Cannabidiol Now Showing Up In Dietary Supplements. Natural Medicines Web site. Available at: https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. Accessed: May 31, 2015.

Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63(7):1245-50. View abstract.

Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30(4):277-82. View abstract.

Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25(1):121-30. View abstract.

Dalterio S, Steger R, Mayfield D, Bartke A. Early cannabinoid exposure influences neuroendocrine and reproductive functions in mice: II. Postnatal effects. Pharmacol Biochem Behav 1984;20(1):115-23. View abstract.

Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55(6):791-802. View abstract.

Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27(1):19-27. View abstract.

Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006;399(1-2):91-5. View abstract.

Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007;151(8):1272-9. View abstract.

FDA and Marijuana: Questions and Answers. U.S. Food and Drug Administration Web site. Available at: https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm421168.htm. Accessed: May 31, 2015.

Formukong EA, Evans AT, Evans FJ. Analgesic and anti-inflammatory activity of constituents of Cannabis sativa L. Inflammation 1988;12(4):361-71. View abstract.

Guimaraes FS, Chairetti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990;100(4):558-9. View abstract.

Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 2004;75(5):633-8. View abstract.

Harvey DJ. Absorption, distribution, and biotransformation of the cannabinoids. Marijuana and Medicine. 1999;91-103.

History. GW Pharmaceuticals Web site. Available at: https://www.gwpharm.com/history.aspx. Accessed: May 27, 2015.

Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: a promising new drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15(1):65-75. View abstract.

Izzo AA, Borelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30(10):515-27. View abstract.

Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;16(11):1349-59. View abstract.

Lee CY, Wey SP, Liao MH, et al. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 2008;8(5):732-40. View abstract.

Leighty EG, Fentiman AF Jr, Foltz RL. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976;14(1):13-28. View abstract.

Leweke FM, Kranaster L, Pahlisch F, et al. The efficacy of cannabidiol in the treatment of schizophrenia – a translational approach. Schizophr Bull 2011;37(Suppl 1):313.

Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94. View abstract.

Long LE, Chesworth R, Huang XF, et al. A behavioral comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010;13(7):861-76. View abstract.

Magen I, Avraham Y, Ackerman Z, et al. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51(3):528-34. View abstract.

Malfait AM, Gallily R, Sumariwalla PF, et al. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97:9561-6. View abstract.

Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as a potential anticancer drug. Br J Clin Pharmacol 2013;75(2):303-12. View abstract.

Matsuyama SS, Fu TK. In vivo cytogenetic effects of cannabinoids. J Clin Psychopharmacol 1981;1(3):135-40. View abstract.

Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002;42(11 Suppl):11S-19S. View abstract.

Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology (Berl) 1977;55(3):263-5. View abstract.

Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychomimetic drugs in mice. Eur J Pharmacol 2005;512(2-3):199-205. View abstract.

Morgan CJ, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013;38(9):2433-6. View abstract.

Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006;580(18):4337-45. View abstract.

Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18(2):219-28. View abstract.

See also  Can Federal Employees Use CBD Oil

Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity cause by multiple sclerosis. Eur J Neurol 2011;18(9):1122-31. View abstract.

Overview. GW Pharmaceuticals Web site. Available at: https://www.gwpharm.com/about-us-overview.aspx. Accessed: May 31, 2015.

Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delat9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215. View abstract.

Pickens JT. Sedative activity of cannabis in relation to its delta’-trans-tetrahydrocannabinol and cannabidiol content. Br J Pharmacol 1981;72(4):649-56. View abstract.

Rosenkrantz H, Fleischman RW, Grant RJ. Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicol Appl Pharmacol 1981;58(1):118-31. View abstract.

Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16(3):469-72. View abstract.

Sativex oromucosal spray. Summary of product characteristics. GW Pharma, Ltd. Available at: https://www.medicines.org.uk/emc/medicine/23262. Updated: May 2015. Accessed: May 31, 2015.

Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol 2014;24(1):51-64. View abstract.

Schubart CD, Sommer IE, van Gastel WA, et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130(1-3):216-21. View abstract.

Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260(1):285-95. View abstract.

Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 2011;10(7):1161-72. View abstract.

Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type 1 diabetic peripheral neuropathic pain. Mol Pain 2010;6:16. View abstract.

Valvassori SS, Elias G, de Souza B, et al. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol 2011;25(2):274-80. View abstract.

Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based treatment in spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12(5):639-45. View abstract.

Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-92. View abstract.

Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011;88(15-16):730-6. View abstract.

Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79(11):1691-8. View abstract.

Yamaori S, Maeda C, Yamamoto I, Watanabe K. Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 2011;29:117-24.

Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39(11):2049-56. View abstract.

Zuardi A, Crippa J, Dursun S, et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 2010;24(1):135-7. View abstract.

Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993;7(1 Suppl):82-8. View abstract.

Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009;23(8):979-83. View abstract.

Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39(4):421-9. View abstract.

Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56(10):485-6. View abstract.

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30(3):271-80. View abstract.

Ames, F. R. and Cridland, S. Anticonvulsant effect of cannabidiol. S.Afr.Med.J. 1-4-1986;69(1):14. View abstract.

Barnes, M. P. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert.Opin.Pharmacother. 2006;7(5):607-615. View abstract.

Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur.J.Neurol. 2007;14(3):290-296. View abstract.

Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol.Res. 2010;32(5):451-459. View abstract.

Consroe, P., Kennedy, K., and Schram, K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem.Behav. 1991;40(3):517-522. View abstract.

Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem.Behav. 1991;40(3):701-708. View abstract.

Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E., McGuire, P. K., and Filho, Busatto G. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004;29(2):417-426. View abstract.

Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., and Fusar-Poli, P. Cannabis and anxiety: a critical review of the evidence. Hum.Psychopharmacol. 2009;24(7):515-523. View abstract.

Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21(3):175-185. View abstract.

Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem.Behav. 1991;40(3):523-532. View abstract.

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A. A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134-141. View abstract.

Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., and Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol.Life Sci. 2006;63(17):2057-2066. View abstract.

Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., and Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp.Ther. 2004;308(3):838-845. View abstract.

Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., and Hollister, L. E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed.Environ Mass Spectrom. 1986;13(2):77-83. View abstract.

Srivastava, M. D., Srivastava, B. I., and Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998;40(3):179-185. View abstract.

Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ’90 International Conference on Cannabis and Cannabinoids 1990;2:5.

Wade, D. T., Collin, C., Stott, C., and Duncombe, P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult.Scler. 2010;16(6):707-714. View abstract.

Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult.Scler. 2004;10(4):434-441. View abstract.

Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin.Rehabil. 2003;17(1):21-29. View abstract.

Watzl, B., Scuderi, P., and Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13(8):1091-1097. View abstract.

Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39(2):143-151. View abstract.

Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol, I. G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982;76(3):245-250. View abstract.

“GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance.” GW Pharmaceuticals, 6 April 2020. https://ir.gwpharm.com/node/11356/pdf. Press release.

97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016 Oct;39(10):1777-86. View abstract.

Agriculture Improvement Act, S. 10113, 115th Cong. (2018) or S. 12619, 115th Cong. (2018).

Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019. View abstract.

Anderson LL, Doohan PT, Oldfield L, et al. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021. View abstract.

Appiah-Kusi E, Petros N, Wilson R, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl). 2020 Jan 8. View abstract.

Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology (Berl). 2019;236(9):2713-2724. View abstract.

Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of Cannabidiol and ?9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020;324(21):2177-2186. View abstract.

Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. The dose-dependent analgesic effects, abuse liability, safety and tolerability of oral cannabidiol in healthy humans. Br J Clin Pharmacol. 2021. View abstract.

Aviello G, Romano B, Borrelli F, et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 2012;90(8):925-34. View abstract.

Baranowska-Kuczko M, Kozlowska H, Kloza M, et al. Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension. Pharmaceuticals (Basel) 2021;14(11):1120. View abstract.

Bass J, Linz DR. A Case of Toxicity from Cannabidiol Gummy Ingestion. Cureus. 2020;12(4):e7688. View abstract.

Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214(8):370-375. View abstract.

Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. CNS Drugs. 2020;34(6):661-672. View abstract.

Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36(6):1219-26. View abstract.

Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol related cases reported in the National Poison Data System – 2019-2020. Am J Emerg Med. 2021;48:218-223. View abstract.

Bergeria CL, Spindle TR, Cone EJ, et al. Pharmacokinetic Profile of ?9-tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products. J Anal Toxicol 2022. View abstract.

Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019 Aug;60(8):1586-1592. View abstract.

Bisogno T, Di Marzo Y. The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses. Curr Pharm Des 2008;14(23):2299-3305. View abstract.

Bloomfield MAP, Green SF, Hindocha C, et al. The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study. J Psychopharmacol. 2020;34(9):981-989. View abstract.

Bloomfield MAP, Yamamori Y, Hindocha C, et al. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. Psychopharmacology (Berl) 2022. View abstract.

Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology (Berl) 2022. View abstract.

Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA 2017 Nov;318(17):1708-9. View abstract.

Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011;51(5):1054-61. View abstract.

Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45(6):1323-31. View abstract.

Brady CM, DasGupta R, Dalton C, et al. An open-label study of cannabis-based extracts for bladder dysfuntion in advanced multiple sclerosis. Mult Scler 2004;10(4):425-33. View abstract.

Campos AC, Guimaraes FS. Activation of 5HT1A receptors mediates the anxiolytic effects of cannabidiol in a PTSD model. Behav Pharmacol 2009;20:S54.

Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012;367(1607):3364-78. View abstract.

Cannabidiol Now Showing Up In Dietary Supplements. Natural Medicines Web site. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. (Accessed May 31, 2015).

Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56-61. View abstract.

Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-27S. View abstract.

Carlini EA, Leite JR, Tannhauser M, Berardi AC. Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973;25(8):664-5. View abstract.

Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I. Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice. Pharmaceuticals (Basel) 2021;14(9):863. View abstract.

Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63(7):1245-50. View abstract.

Carvalho RK, Rocha TL, Fernandes FH, et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: New insights of cannabidiol-mediated male reproductive toxicity. Chem Biol Interact 2022;351:109743. View abstract.

Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS. Cannabidiol inhibitory effect on marble-burying behavior: involvement of CB1 receptors. Behav Pharmacol 2010;21(4):353-8. View abstract.

Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020. View abstract.

Cochrane-Snyman KC, Cruz C, Morales J, Coles M. The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men. Med Sci Sports Exerc. 2021. View abstract.

Cole TB, Saitz R. Cannabis and Impaired Driving. JAMA. 2020;324(21):2163-2164. View abstract.

Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30(4):277-82. View abstract.

Consroe P, Wolkin A. Cannabidiol-antiepilpetic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201(1):26-32. View abstract.

Consroe PF, Wokin AL. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977;29(8):500-1. View abstract.

Cortopassi J. Warfarin dose adjustment required after cannabidiol initiation and titration. Am J Health Syst Pharm. 2020;77(22):1846-1851. View abstract.

Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O’Sullivan SE. Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019;25(6):1006-1018. View abstract.

Covington TR, et al. Handbook of Nonprescription Drugs. 11th ed. Washington, DC: American Pharmaceutical Association, 1996.

Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25(1):121-30. View abstract.

Crippa JAS, Pacheco JC, Zuardi AW, et al. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis Cannabinoid Res 2021. View abstract.

Crippa JAS, Zuardi AW, Guimarães FS, et al. Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. View abstract.

Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 2020;61(2):267-277. View abstract.

Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23(5):238-45. View abstract.

Czégény Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Rep 2021;11(1):8951. View abstract.

Dalton WS, Martz R, Lemberger L, et al. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 1976;19(3):300-9. View abstract.

Darweesh RS, Khamis TN, El-Elimat T. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020. View abstract.

Davis BH, Beasley TM, Amaral M, et al. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy. Clin Pharmacol Ther 2021;110(5):1368-1380. View abstract.

de Almeida CMO, Brito MMC, Bosaipo NB, et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Mov Disord. 2021. View abstract.

de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 2020;102:106635. View abstract.

de Faria SM, de Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 2020 Jan 7:269881119895536. View abstract.

De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One 2011;6(12):e28159. View abstract.

Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55(6):791-802. View abstract.

Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. View abstract.

Devinsky O, Kraft K, Rusch L, Fein M, Leone-Bay A. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study. J Pharm Sci 2021. View abstract.

Devinsky O, Marsh E, Friedman D, et la. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. View abstract.

Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-1897. View abstract.

Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018 Sep;86:131-137. Epub 2018 Jul 11. View abstract.

Dieterle M, Zurbriggen L, Mauermann E, et al. Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II). Pain 2022. View abstract.

Drug Enforcement Administration, Department of Justice. Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements. Final order. Fed Regist. 2018 Sep 28;83(189):48950-3. View abstract.

Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. Pediatr Neurol. 2020;105:59-61. View abstract.

El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 2010;95(4):434-42. View abstract.

El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006;168(1):235-44. View abstract.

Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27(1):19-27. View abstract.

Epidiolex (cannabidiol) prescribing information. Greenwich Biosciences, Inc., Carlsbad, CA, 2019. Available at: https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (accessed 5/9/2019)

Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006;399(1-2):91-5. View abstract.

Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007;151(8):1272-9. View abstract.

FDA Consumer Updates: What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding. U. S. Food and Drug Administration (FDA). October 2019. Available at: https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.

Formukong EA, Evans AT, Evans FJ. Analgesic and anti-inflammatory activity of constituents of Cannabis sativa L. Inflammation 1988;12(4):361-71. View abstract.

Freeman TP, Hindocha C, Baio G, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020; 7(10):865-874. View abstract.

Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010;13(4):421-32. View abstract.

Gaston TE, Ampah SB, Martina Bebin E, et al. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy Behav. 2021;117:107862. View abstract.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017 Sep;58(9):1586-92. View abstract.

Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015 Aug;56(8):1246-51. View abstract.

Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017 Jan;32(1):35-40. View abstract.

Granjeiro EM, Gomes FV, Guimaraes FS, et al. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav 2011;99(4):743-8. View abstract.

Guimaraes FS, Chairetti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990;100(4):558-9. View abstract.

Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 2004;75(5):633-8. View abstract.

Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M. Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi. J Diet Suppl. 2020;17(5):599-607. View abstract.

Hacke ACM, Lima D, de Costa F, et al. Probing the antioxidant activity of [delta](9)-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. Analyst. 2019;144(16):4952-4961. View abstract.

See also  CBD Oil Plant Ultrasonic Extraction Equipment

Haffar A, Khan IA, Abdelaal MS, Banerjee S, Sharkey PF, Lonner JH. Topical Cannabidiol (CBD) After Total Knee Arthroplasty Does Not Decrease Pain or Opioid Use: A Prospective Randomized Double-Blinded Placebo-Controlled Trial. J Arthroplasty 2022. View abstract.

Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998;95(14):8268-73. View abstract.

Harris HM, Gul W, ElSohly MA, Sufka KJ. Differential Effects of Cannabidiol and a Novel Cannabidiol Analog on Oxycodone Place Preference and Analgesia in Mice: an Opioid Abuse Deterrent with Analgesic Properties. Cannabis Cannabinoid Res 2021. View abstract.

Harvey DJ. Absorption, distribution, and biotransformation of the cannabinoids. Marijuana and Medicine. 1999;91-103.

Hazekamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018 Jun;1:65-72.

Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016 Oct;57(10):1617-24.View abstract.

Heussler H, Cohen J, Silove N, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019;11(1):16. View abstract.

Hobbs JM, Vazquez AR, Remijan ND, et al. Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults. Phytother Res. 2020;34(7):1696-1703. View abstract.

Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol. 2020. View abstract.

Hotz J, Fehlmann B, Papassotiropoulos A, de Quervain DJ, Schicktanz NS. Cannabidiol enhances verbal episodic memory in healthy young participants: A randomized clinical trial. J Psychiatr Res 2021;143:327-333. View abstract.

Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019:appiajp201918101191. View abstract.

Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R. Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study. Epilepsy Behav. 2020 Jan;102:106826. View abstract.

Isenmann E, Veit S, Starke L, Flenker U, Diel P. Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training. Nutrients 2021;13(9):3028. View abstract.

Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: a promising new drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15(1):65-75. View abstract.

Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. Eur J Pharm Biopharm. 2020;154:108-115. View abstract.

Izzo AA, Borelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30(10):515-27. View abstract.

Jacobsson SO, Rongard E, Stridh M, et al. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 2000;60(12):1807-13. View abstract.

Jones É, Vlachou S. Cannabidiol Does Not Cause Significant Changes to Working Memory Performance in the N-Back Task. Pharmaceuticals (Basel) 2021;14(11):1165. View abstract.

Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol treatment for refractory seizures in Sturge-Weber Syndrome. Pediatr Neurol. 2017 Jun;71:18-23.e2. View abstract.

Karler R, Cely W, Turkanis SA. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci 1973;13(11):1527-31. View abstract.

Karler R, Turkanis SA. Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 1980;68(3):479-84. View abstract.

Karoly HC, Mueller RL, Andrade CC, Hutchison KE. THC and CBD effects on alcohol use among alcohol and cannabis co-users. Psychol Addict Behav. 2021. View abstract.

Kaufmann R, Aqua K, Lombardo J, Lee M. Observed Impact of Long-term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. Cannabis Cannabinoid Res 2021. View abstract.

Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;16(11):1349-59. View abstract.

Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy. Front Neurol. 2019 Dec 10;10:1313. View abstract.

Klotz KA, Grob D, Schönberger J, et al. Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study. CNS Drugs 2021;35(11):1207-1215. View abstract.

Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019;60(7):e74-e77. View abstract.

Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects. Molecules. 2019;24(16). pii: E2967. View abstract.

Köck P, Lang E, Trulley VN, et al. Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study. Front Psychiatry 2021;12:736822. View abstract.

Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Epilepsia. 2020;61(6):1090-1098. View abstract.

Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019;154:13-20. View abstract.

Lee CY, Wey SP, Liao MH, et al. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 2008;8(5):732-40. View abstract.

Leehey MA, Liu Y, Hart F, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. Cannabis Cannabinoid Res. 2020;5(4):326-336. View abstract.

Leighty EG, Fentiman AF Jr, Foltz RL. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976;14(1):13-28. View abstract.

Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant. 2019;19(10):2944-2948. View abstract.

Leweke FM, Kranaster L, Pahlisch F, et al. The efficacy of cannabidiol in the treatment of schizophrenia – a translational approach. Schizophr Bull 2011;37(Suppl 1):313.

Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94. View abstract.

Leweke FM, Rohleder C, Gerth CW, Hellmich M, Pukrop R, Koethe D. Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Front Pharmacol. 2021;12:614811. View abstract.

Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006;318(3):1375-87. View abstract.

Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019 Jan-Feb;41(1):9-14. Epub 2018 Oct 11. View abstract.

Long LE, Chesworth R, Huang XF, et al. A behavioral comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010;13(7):861-76. View abstract.

Lopez HL, Cesareo KR, Raub B, et al. Effects of hemp extract on markers of wellness, stress resilience, recovery and clinical biomarkers of safety in overweight, but otherwise healthy subjects. J Diet Suppl. 2020;17(5):561-86. View abstracts.

Madan Cohen J, Checketts D, Dunayevich E, et al. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. Epilepsia 2021;62(9):2218-2227. View abstract.

Madden K, Tanco K, Bruera E. Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol. Pediatrics. 2020;e20193256. View abstract.

Magen I, Avraham Y, Ackerman Z, et al. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51(3):528-34. View abstract.

Maghfour J, Rundle CW, Rietcheck HR, et al. Assessing the effects of topical cannabidiol in patients with atopic dermatitis. Dermatol Online J. 2021;27(2):13030/qt8h50k2vs. View abstract.

Malfait AM, Gallily R, Sumariwalla PF, et al. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97:9561-6. View abstract.

Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 2009;93(2):91-6. View abstract.

Martin RC, Gaston TE, Thompson M, et al. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy Behav. 2019;97:105-110. View abstract.

Masataka N. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Front Psychol. 2019 Nov 8;10:2466. View abstract.

Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as a potential anticancer drug. Br J Clin Pharmacol 2013;75(2):303-12. View abstract.

Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008;104(4):1091-100. View abstract.

Masterson D. CBD from orange peels: A different CBD story. August 3, 2021. Available at: https://www.nutraingredients-usa.com/Article/2021/08/03/CBD-from-orange-peels-A-different-CBD-story?utm_source=newsletter_daily&utm_medium=email&utm_campaign=03-Aug-2021&cid=DM973784&bid=1668435211. Accessed October 26, 2021.

McAllister SD, Christian RT, Horowitz MP, et al. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007;6(11):2921-7. View abstract.

McAllister SD, Murase R, Christian RT, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011;129(1):37-47. View abstract.

McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.Am J Psychiatry. 2018;175(3):225-231. View abstract.

McNamara NA, Dang LT, Sturza J, et al. Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid. Epilepsia. 2020. View abstract.

Miller I, Scheffer IE, Gunning B, et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77(5):613-621. View abstract.

Miller OS, Elder EJ Jr, Jones KJ, Gidal BE. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Epilepsy Behav 2022;127:108514. View abstract.

Mongeau-Pérusse V, Rizkallah E, Morissette F, et al. Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial. J Addict Med 2022. View abstract.

Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology (Berl) 1977;55(3):263-5. View abstract.

Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(8):1466-71. View abstract.

Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychomimetic drugs in mice. Eur J Pharmacol 2005;512(2-3):199-205. View abstract.

Morgan CJ, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013;38(9):2433-6. View abstract.

Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8(8):1009-1031. View abstract.

Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006;580(18):4337-45. View abstract.

Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment of Crohn’s Disease, a randomized controlled trial. Dig Dis Sci. 2017 Jun;62(6):1615-20. View abstract.

Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metab Dispos 2021;49(12):1070-1080. View abstract.

Nguyen LC, Yang D, Nicolaescu V, et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv 2022. View abstract.

Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019 Nov 6;8(11). pii: E1886. View abstract.

Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18(2):219-28. View abstract.

Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity cause by multiple sclerosis. Eur J Neurol 2011;18(9):1122-31. View abstract.

Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990;253(3):1002-9. View abstract.

Oruganti P, Betcher S, Wakade Z, Ding X, Abegunde AT. Cannabidiol Oil-Associated Microscopic Colitis. Cureus. 2020;12(9):e10528. View abstract.

Overview. GW Pharmaceuticals Web site. Available at: https://www.gwpharm.com/about-us-overview.aspx. Accessed: May 31, 2015.

Parihar V, Rogers A, Blain AM, Zacharias SRK, Patterson LL, Siyam MA. Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction. J Pharm Pract. 2020:897190020972208. View abstract.

Partridge Snow & Hahn LLP. FDA Refuses to Approve CBVD As a Food Ingredient or Supplement. August 19, 2021. Available at: https://www.jdsupra.com/legalnews/fda-refuses-to-approve-cbd-as-a-food-1880558. Accessed October 26, 2021.

Patel AD, Mazurkiewicz-Beldzinska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62(9):2228-2239. View abstract.

Patrician A, Versic-Bratincevic M, Mijacika T, et al. Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study. Adv Ther. 2019. View abstract.

Pavlovic R, Nenna G, Calvi L, et al. Quality Traits of “Cannabidiol Oils”: Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations. Molecules. 2018 May 20;23(5). pii: E1230. View abstract.

Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delat9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215. View abstract.

Pickens JT. Sedative activity of cannabis in relation to its delta’-trans-tetrahydrocannabinol and cannabidiol content. Br J Pharmacol 1981;72(4):649-56. View abstract.

Poklis JL, Mulder HA, Peace MR. The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids. Forensic Sci Int. 2019 Jan;294:e25-e27. Epub 2018 Nov 1. View abstract.

Pretzsch CM, Freyberg J, Voinescu B, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019;44(8):1398-1405. View abstract.

Pretzsch CM, Voinescu B, Mendez MA, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol. 2019:269881119858306. View abstract.

Product information for Marinol. AbbVie. North Chicago, IL 60064. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.

Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010;56(25):2115-25. View abstract.

Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates high glucose-induces endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 2007;293(1):H610-H619. View abstract.

Resstel LB, Joca SR, Moreira FA, et al. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 2006;172(2):294-8. View abstract.

Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioral and cardiovascular responses to acute stress in rats. Br J Pharmacol 2009;156(1):181-8. View abstract.

Rianprakaisang T, Gerona R, Hendrickson RG. Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. Clin Toxicol (Phila). 2020;58(3):215-216. View abstract.

Sahinovic A, Irwin C, Doohan PT, et al. Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. Sports Med Open 2022;8(1):27. View abstract.

Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16(3):469-72. View abstract.

Santos de Alencar S, Crippa JAS, Brito MCM, Pimentel ÂV, Cecilio Hallak JE, Tumas V. A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Parkinsonism Relat Disord. 2021;83:37-40. View abstract.

Scheffer IE, Halford JJ, Miller I, et al. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62(10):2505-2517. View abstract.

Scheffer IE, Hulihan J, Messenheimer J, et al. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA Netw Open 2021;4(9):e2123930. View abstract.

Schneider T, Zurbriggen L, Dieterle M, et al. Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I). Pain. 2021. doi: 10.1097/j.pain.0000000000002310. View abstract.

Schoedel KA, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav. 2018 Nov;88:162-171. doi: 10.1016/j.yebeh.2018.07.027. Epub 2018 Oct 2. View abstract.

Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol 2014;24(1):51-64. View abstract.

Schubart CD, Sommer IE, van Gastel WA, et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130(1-3):216-21. View abstract.

Sepulveda DE, Morris DP, Raup-Konsavage WM, Sun D, Vrana KE, Graziane NM. Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Combination with Morphine Using the Formalin Test in Male and Female Mice. Cannabis Cannabinoid Res 2021. View abstract.

Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260(1):285-95. View abstract.

Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 2011;10(7):1161-72. View abstract.

Singh RK, Dillon B, Tatum DA, Van Poppel KC, Bonthius DJ. Drug-Drug Interactions Between Cannabidiol and Lithium. Child Neurol Open. 2020;7:2329048X20947896. View abstract.

Spinella TC, Stewart SH, Naugler J, Yakovenko I, Barrett SP. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study. Psychopharmacology (Berl). 2021. View abstract.

Statement from FDA Commissioner Scot Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency’s regulation of products containing cannabis and cannabis-derived compounds. U.S. Food and Drug Administration Web site. Available at: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Accessed May 7, 2019).

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018 Oct;87:131-136. Epub 2018 Aug 9. View abstract.

Szaflarski JP, Hernando K, Bebin EM, et al. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy Behav. 2019;95:131-136. View abstract.

Taylor L, Crockett J, Tayo B, Checketts D, Sommerville K. Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav. 2020;104(Pt A):106938. View abstract.

Taylor L, Crockett J, Tayo B, Morrison G. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. J Clin Pharmacol. 2019;59(8):1110-1119. View abstract.

Thai C, Tayo B, Critchley D. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. Clin Pharmacol Drug Dev. 2021. View abstract.

Thiele EA, Bebin EM, Bhathal H, et al. Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2020. View abstract.

Thiele EA, Bebin EM, Filloux F, et al. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. Epilepsia 2021. View abstract.

Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085-1096. View abstract.

Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10(1):90-103. View abstract.

Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type 1 diabetic peripheral neuropathic pain. Mol Pain 2010;6:16. View abstract.

Uribe-Marino A, Francisco A, Castiblanco-Urbina MA, et al. Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology 2012;37(2):412-21. View abstract.

Valenti M, Massi P, Bolognini D, et al. Cannabidiol, a non-psychoactive cannabinoid compound inhibits human glioma cell migration and invasiveness. 34th National Congress of the Italian Society of Pharmacology 2009.

Valvassori SS, Elias G, de Souza B, et al. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol 2011;25(2):274-80. View abstract.

van Orten-Luiten AB, de Roos NM, Majait S, Witteman BJM, Witkamp RF. Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. Cannabis Cannabinoid Res. 2021. View abstract.

Vela J, Dreyer L, Petersen KK, Lars AN, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial. Pain 2021. View abstract.

Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18(3):e1003524. View abstract.

Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based treatment in spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12(5):639-45. View abstract.

Wang GS, Bourne DWA, Klawitter J, et al. Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. Clin Pharmacokinet. 2020. View abstract.

Watkins PB, Church RJ, Li J, Knappertz V. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. Clin Pharmacol Ther. 2020. View abstract.

Wiemer-Kruel A, Stiller B, Bast T. Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex. Neuropediatrics. 2019. View abstract.

Woelfl T, Rohleder C, Mueller JK, et al. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. Front Psychiatry. 2020;11:576877. View abstract.

Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2019 Dec 1. View abstract.

Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-92. View abstract.

Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011;88(15-16):730-6. View abstract.

See also  Cbg CBD Oil

Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79(11):1691-8. View abstract.

Yamaori S, Maeda C, Yamamoto I, Watanabe K. Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 2011;29:117-24.

Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39(11):2049-56. View abstract.

Yeshurun M, Shpilberg O, Herscovici C, et al. Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant. 2015 Oct;21(10):1770-5. View abstract.

Yu JS, Premkumar A, Liu S, Sculco P. Rates of self-directed perioperative cannabidiol use in patients undergoing total hip or knee arthroplasty. Pain Manag 2021;11(6):655-660. View abstract.

Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993;7(1 Suppl):82-8. View abstract.

Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009;23(8):979-83. View abstract.

Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39(4):421-9. View abstract.

Zuardi AW, Rodriguez JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991;104(2):260-4. View abstract.

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30(3):271-80. View abstract.

Can CBD Oil Cause Dry Mouth?

Do you regularly experience dry mouth after taking CBD? You’re not alone.

In fact, this effect is common for all cannabinoids, not only for CBD. But does it mean that cannabis users just have to accept it and go on with their supplementation?

Or is there a way to minimize the dry mouth effect after using CBD oils and vapes?

There are at least a few ways to help you cope with the cottonmouth.

It’s just so common that hardly anyone is questioning the mechanism at work.

Today, we explain why CBD gives you the dry mouth feeling and how to cope with it using some simple tricks.

Why Does CBD Cause Dry Mouth (Cottonmouth)

Several factors can cause dry mouth after taking CBD oil or any cannabis-based product. This section holds the answer to the “why” behind the cottonmouth effect.

Cannabinoids Affect Salivary Glands

Several studies point to cannabis use as the reason for having a dry mouth. A 1986 study on the effects of CBD noted that the side effects of oral CBD included dry mouth.

Since then, a few other studies have investigated this effect. Oral dryness even has a scientific name — xerostomia.

Perhaps the most relevant study on CBD-induced oral dryness comes from the researchers at the University of Buenos Aires, Argentina, in 2006. The authors found that cannabinoid receptors type 1 and 2 (CB1 and CB2) occur in the submandibular glands, which lie beneath the bottom of the mouth and are responsible for the secretion of 60-67% of the saliva (1).

The research team found that anandamide, which is one of the two major endocannabinoids produced by the body, binds with high affinity to these cannabinoid receptors and blocks the secretion of saliva.

Both THC and CBD interact with the cannabinoid receptors of the parasympathetic nervous system, so they’re likely to affect the receptors of the submandibular glands in a similar fashion.

CBD May Signal Your Brain to Slow Down Saliva Production

The said study also concluded that the role of the endocannabinoid system reaches beyond simply blocking signals at the submandibular glands themselves. The nervous signals are first created in the brain.

The researchers drew out a hypothesis that intravenous application of cannabinoids through the femoral vein not only blocked the saliva secretion in the submandibular gland but it may also have interacted with the CB1 and CB2 receptors in the brain itself. They proposed that the central nervous system helps to control saliva production at the glandular level.

Impurities in CBD Oil

Contaminated CBD oils can contain dangerous byproducts, causing serious health risks. These contaminants can cause irritation in the mouth and lungs, resulting in dry mouth or irritation of the oral tract.

If you’re experiencing severe discomfort caused by the dryness, itchiness, or swelling of your mouth and throat — seek medical attention immediately. This isn’t a normal side effect of CBD oil.

Too High a Dose

Agencies responsible for regulating food safety have advised users not to exceed a dose of 100 mg of CBD daily for healthy adults. Breaching this threshold can lead to side effects like dry mouth.

Smoking Cannabis

Different forms of CBD can produce various side effects. For example, smoking CBD flowers or dabbing CBD concentrates can irritate your mouth, throat, and lungs, causing coughing and dryness in the mouth for some individuals.

Using Sprays and Tinctures

Using sublingual forms of CBD, such as sprays or tinctures, causes the CBD to absorb through the mucous membrane in the mouth. From there, CBD can reach the cannabinoid receptors in your salivary gland, inhibiting saliva secretion and causing dry mouth.

Taking these forms of CBD more frequently can cause regular discomfort in the mouth and even an unpleasant stinging sensation in some cases.

Vaping CBD

Vaping CBD is considered safer than smoking because it produces fewer toxic byproducts such as carcinogens. However, the flavorings and thinning agents used in vape oils can cause serious health risks. Moreover, when you vape CBD, it also reaches your salivary glands, thus reducing saliva secretion in the mouth.

How to Cope with Dry Mouth from CBD?

As you can see, CBD and dry mouth come hand in hand, so it’s no wonder why people are seeking ways to cope with this side effect.

Worse yet, you don’t need to take much CBD in order to experience dryness in the mouth. For heavy CBD users, this side effect is their daily companion — and an annoying one, to be honest.

Preventing cottonmouth is better than having to fight it when it appears. Here are a few ways to help yourself cope and de-escalate this unpleasant sensation before it becomes a pain in the mouth.

1. Hydrate Yourself

The best method for preventing or reducing the offset of cottonmouth while using CBD oil is to drink a lot of water and take care of proper hydration throughout the day. Also, drinking other hydrating liquids such as electrolytes right before, during, and after taking CBD oil can help diminish this annoying problem to some extent. Drinking herbal teas and warm water is the best for hydration and easing sore throat.

2. Increase Saliva Production

Try using toothpaste, lozenges, or lollipops to combat mouth dryness by increasing saliva production. Sucking on lollipops or hard candies stimulates your salivary glands to produce more saliva and creates a moist film lining the mucous membranes and preventing dryness in the mouth and throat.

3. Chew Gum

Choosing CBD-infused chewing gum is one of the best ways to avoid dry mouth. The CBD gets absorbed right into the bloodstream through the capillaries located under the tongue. Most natural CBD gum supplements are sugar-free and don’t contain artificial ingredients such as sweeteners or aromas. They rather use peppermint essential oil and xylitol as flavorings.

Another method to effectively cope with dry mouth is by chewing gums that contain xylitol. This natural sweetener helps activate salivary glands and pumps up the production of saliva in the mouth.

You can find CBD chewing gum in different potencies, so make sure to follow the recommended dosage to avoid cottonmouth.

4. Eat Fruit

Fresh citrus fruits, such as lemon, orange, or pineapple, can help you get rid of the dry mouth feeling. Chewing on dry fruits, ice cubes, or beef jerky will also help activate salivary glands and reduce this side effect to a great extent — especially if you keep yourself hydrated throughout the day.

5. Try Another Form of CBD

When taking CBD oil, it’s best to go with oral or topical forms if you want to avoid experiencing a dry mouth. There are a lot of CBD products that don’t require you to smoke or vape them. This not only protects your lungs but also prevents cottonmouth from occurring.

How Is Saliva Formed?

To elaborate on the subject of CBD and dry mouth, let’s take a look at how saliva is formed.

Saliva formation occurs at two stages.

First, certain cells known as acinar cells form a fluid that has a similar composition to plasma. This fluid then moves through the salivary ducts to enter the oral cavity, and once it succeeds, sodium chloride is removed from it, and potassium and bicarbonate are added.

This stage is known as the final hypotonic solution that is secreted in the salivary glands.

Saliva secretion is managed by the parasympathetic nervous system (PSNS). The PSNS often controls different metabolic processes linked to appetite, food intake, and anticipation of eating.

Salivary receptors are activated by impulses from the chorda tympani nerve. This essential nerve stems from the taste buds before traveling through the cluster of nerve cells located in the submandibular gland.

The chorda tympani nerve produces a compound called acetylcholine, which is one of the body’s main saliva-inducing substances and works directly on the receptors of the submandibular gland.

Another important factor involved in the formation of saliva is norepinephrine. This compound is produced by the preganglionic nerves and works directly on the myoepithelial cells that surround the acinar cells; this contact results in saliva secretion.

Other Side Effects of CBD

Although CBD is generally safe and well-tolerated, it also has some mild side effects. Patients on medications such as blood thinners should consult a doctor before buying CBD products because CBD can interact with different medicines and cause adverse effects.

Here are some of the most common negative reactions to CBD.

Dizziness

Since CBD is a decent sleep aid, it’s no wonder that people experience sedation or drowsiness, especially when taking CBD products in high doses. It’s recommended to adjust your schedule and try taking it in the evening or right before bed so that you can normally function throughout the day (2).

Changes in Appetite

CBD has a biphasic nature, meaning that it can produce different effects in the same individual depending on the conditions under which it is used. Some studies point to CBD as a mild appetite suppressant, while others have found that CBD can actually increase appetite. It’s best to monitor your body’s response to CBD, and if you notice any changes in your appetite, try to adjust the dosage so that it doesn’t cause such fluctuations (3).

Low Blood Pressure

A 2017 study found that a single dose of CBD can lower blood pressure in healthy individuals — both when at rest and when put under stressful situations. This side effect can be risky for people diagnosed with low blood pressure or those who take blood thinners as part of their medication (4).

When this side effect occurs, you may feel lightheaded or drowsy. Lie down and drink plenty of liquids to help stabilize blood pressure if CBD lowers it too much.

Avoid physical activity during that time. In case of fainting, you could injure yourself or other people around you.

Diarrhea

Some users report indigestion or diarrhea after consuming CBD. This unfortunate side effect occurs when you take too much CBD oil, which can further irritate the gastrointestinal tract and trigger diarrhea. Studies have found that diarrhea occurs in people who take more than 300 mg of CBD oil at a time (5).

Key Takeaways on CBD and Dry Mouth

CBD can lead to dry mouth due to its interaction with cannabinoid receptors located in the salivary glands in your mouth.

When you don’t use CBD as recommended, these supplements can cause adverse reactions, such as dry mouth feeling. Usually, the more you take it, the more apparent this side effect will be.

Make sure that you use a clean CBD product, use chewing gum, eat fruit, and stay hydrated if you want to prevent or reduce the intensity of the dry mouth feeling.

Certain types of CBD, such as tinctures and vapes, can make this sensation even more annoying, so if that’s your case, we suggest that you switch to an oral or topical form.

Regardless of your choice, always check for the certificates of analysis for any CBD product out there. Doing so will help you confirm the product’s potency and purity — ensuring that you’re not ingesting any unwanted chemicals alongside your hemp extract.

How do you deal with CBD and dry mouth? Share your life hacks in the comment section below!

References:

  1. Prestifilippo, J. P., Fernández-Solari, J., de la Cal, C., Iribarne, M., Suburo, A. M., Rettori, V., McCann, S. M., & Elverdin, J. C. (2006). Inhibition of salivary secretion by activation of cannabinoid receptors. Experimental biology and medicine (Maywood, N.J.), 231(8), 1421–1429. https://doi.org/10.1177/153537020623100816
  2. Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente journal, 23, 18–041. https://doi.org/10.7812/TPP/18-041
  3. Kirkham T. C. (2009). Cannabinoids and appetite: food craving and food pleasure. International review of psychiatry (Abingdon, England), 21(2), 163–171. https://doi.org/10.1080/09540260902782810
  4. Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI insight, 2(12), e93760. https://doi.org/10.1172/jci.insight.93760
  5. Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and cannabinoid research, 2(1), 139–154. https://doi.org/10.1089/can.2016.0034
Nina Julia

Nina created CFAH.org following the birth of her second child. She was a science and math teacher for 6 years prior to becoming a parent — teaching in schools in White Plains, New York and later in Paterson, New Jersey.

Can CBD Cause Dry Mouth?

Do CBD supplements leave an unpleasant dryness in your mouth? Here’s why it happens and what you can do about this constant dry and pasty mouth sensation.

Article By

From pills to gummies, CBD is gaining popularity due to its seemingly endless health benefits. Though CBD products are considered safe for human consumption, it comes with a few side effects.

Whether you consume CBD for medicinal or recreational purposes, these products often result in a dry mouth or what’s known as cottonmouth. Here’s why it happens and what you can do about it.

Table of Contents

Why Does CBD Cause Dry Mouth (CottonMouth)?

Though CBD causes minimal side effects, it’s impossible to disregard the fact that this cannabis product is responsible for the most common adverse effect – dry mouth.

For some, dry mouth can last for a couple of hours or until the effects of the CBD wear off.

Cannabis Affects the Salivary Glands

The dry sensation occurs when the CBD products inhibit the secretion of saliva in the mouth.

The CBD oil alters how the salivary glands respond and prevent them from secreting the regularly required amount of saliva in the mouth. This results in irritability and pain on the tongue and mouth, making you feel more thirsty.

Presence of Impurities

Impure CBD can contain toxic byproducts, causing severe health hazards. These impurities can irritate the mouth and lungs, leading to cottonmouth or irritation of the mouth and throat.

If you’re experiencing severe dry mouth, itchiness, or swelling of your mouth and throat — visit a doctor immediately; this is not a normal side effect of CBD.

Incorrect Dosage

Numerous food safety agencies have advised users not to exceed 80 – 90 mg of CBD daily for healthy adults. Exceeding this can cause side effects like cottonmouth.

Smoking

Different CBD forms result in various side effects. For instance, smoking or dabbing CBD can damage your lungs and cause sore throat, severe coughing, and dryness in the mouth for some users.

Using Sprays & Tinctures

CBD-infused sprays and tinctures are applied directly into the mouth and quickly reach the salivary glands, causing dry mouth.

Using these CBD forms more frequently can cause an unpleasant stinging sensation and burns, in some cases.

Vape Inhalation

Vaping CBD is much safer than smoking as it produces less toxic byproducts. However, the thinning agents and flavoring additives used in vaping oil pose serious health hazards.

When vaped, these harmful additives may result in cottonmouth, severe cough, and lung injuries for some users.

What Can I Do About Dry Mouth From CBD?

Experiencing dryness in the mouth and throat after ingesting CBD is quite common. It often doesn’t take much CBD consumption to induce this adverse effect. Heavy CBD users may experience a constant dry mouth effect, which can be highly annoying.

Preventing cottonmouth is better than having to combat it when it happens. Here are a few remedies that can help de-escalate this unpleasant experience before it escalates.

1. Stay Hydrated

The best way to reduce or prevent the offset of cottonmouth while using CBD oil is to consume plenty of water and keep yourself hydrated throughout the day. Also, drinking other hydrating liquids immediately before, during, and after consuming CBD can help mitigate this annoying issue to a certain extent. Drinking warm herbal teas can keep you hydrated and prevent an irritated or sore throat.

2. Increase Saliva Production

Using toothpaste and lozenges that promote saliva production can help mouth dryness. Sucking on hard candies or lollipops is also helpful. Taking demulcent cough drops will create a moist film coating on the mucous membranes and prevent dryness in the throat and mouth.

3. Chew Gum

Opting for CBD-infused chewing gum is one of the best and innovative ways to include this supplement in your diet. The CBD gets absorbed directly into the bloodstream through the capillaries present in your tongue. Most natural CBD gum supplements do not contain artificial ingredients and are flavored with peppermint essential oil and xylitol.

Another method to effectively cure cottonmouth is by chewing gums that contain xylitol. This natural sugar helps stimulate the salivary glands and increases the production of saliva in the mouth.

These CBD chewing gums are available in different potencies, so stick to the recommended dosage to avoid this effect.

4. Try Another Form of CBD

When using CBD, opt for topical or oral consumption instead of vape or smoke inhalation. Numerous CBD products are available that do not require vaping or smoking. This protects your lungs and prevents harmful components like carbon monoxide from infiltrating your bloodstream.

Ingesting CBD capsules, oils, and edibles is less harmful and prevent dryness in the mouth and sore throat. Also, CBD gels, lotions, balms, and creams can prevent CBD from causing the dry effect in the mouth, as it only acts on the site of application.

5. Eat Fruit

Fresh citrus fruits like orange, pineapple, or lemon can help eliminate dry mouth. Some individuals claim that drinking pineapple juice has helped. However, you can try different fruit juices to find out which one is effective for you.

Chewing on dry fruits, beef jerky, or sucking ice cubes will also help stimulate saliva production and keep your mouth well hydrated, reducing this side effect to a great extent.

Other Side Effects of CBD

Though CBD has a good tolerance and side effect profile, it’s not free from adverse effects. Generally, CBD products are considered safe for oral consumption or topical application. In some cases, it can cause mild side effects.

Patients on medications such as blood thinners need to be careful as CBD can interact with different medicines and cause adverse reactions.

Here are some of the most common side effects of CBD.

Gastrointestinal Problems

Some users experience indigestion or diarrhea while consuming CBD.

This unfortunate symptom happens when the oil affects the gastrointestinal tract, leading to diarrhea. Such individuals need to monitor their medical history while using CBD.

Drowsiness

Since CBD is an excellent treatment for insomnia, it’s no surprise that users experience sedation or drowsiness while taking CBD products. It’s advisable to adjust your schedule and try taking it before bed.

Low Blood Pressure

Consuming higher doses of CBD can lower blood pressure. This can be risky for individuals diagnosed with low blood pressure or those on medication for high blood pressure.

When this happens, you may feel dizzy or lightheaded. Drink plenty of fluids and lie down to help stabilize blood pressure if this happens to you.

Avoid moving around too much. If you faint, you could seriously injure yourself or others.

Nausea

Some users may feel nauseous while ingesting CBD products. This varies based on the amount of CBD you consume and how sensitive your body is to CBD oil.

Summary: Does CBD Cause Dry Mouth?

CBD can cause dry mouth but be it over-the-counter or prescribed, CBD supplements can cause adverse reactions if not used as recommended. Usually, the benefits and side effects of CBD are unique for each individual.

Adjusting your dose, chewing gum, eating fruit, and staying hydrated are just a few ways you can help or prevent cottonmouth.

As the body type of each individual is different, the cure won’t look the same for everyone. What works perfectly for one CBD user may not function the same for another. You need to consult your physician before you start consuming CBD supplements daily to minimize unwanted risks.

To avoid severe side effects from impure CBD, purchase your CBD supplements from a certified source. This is the only way you know your product is pure, potent, and will give you the benefits you’re after.

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.